Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
01 2020
Historique:
received: 13 09 2019
revised: 08 11 2019
accepted: 09 11 2019
pubmed: 26 11 2019
medline: 21 10 2020
entrez: 26 11 2019
Statut: ppublish

Résumé

HPV mediated head and neck squamous cell carcinoma (HPVmHNSCC) is increasing in prevalence in the United States, as are reports of patients with multiple HPVmHNSCCs. The prevalence, demographics, and treatment implications of this emerging clinical entity are poorly understood. We performed a multitiered assessment of patients with multiple HPVmHNSCC including: 1. systematic review of the literature, 2. query of the 2017 Surveillance, Epidemiology and End Results (SEER) database and 3. institutional level reporting at two high volume academic centers. Systematic literature review: 13 articles met inclusion criteria (48 patients with multiple HPVmHNSCC). Pooled prevalence rate of multiple HPVmHNSCC was 2.64%. SEER database: 60(0.95%) patients with HPVmHNSCC had two tumors. Patients with multiple HPVmHNSCC were more likely to be younger and present with a lower T and N stage (p < 0.025 for all). The second identified tumor was more likely to be contralateral, found synchronously, of smaller size, and to occur in the tonsil (p < 0.05 for all). Institutional reporting: 17(1.69%) patients with HPVmHNSCC had two primary tumors. Similar to the SEER database, patients with multiple HPVmHNSCC were more likely to present with a low T stage and tonsil location (p < 0.007 for both). Multiple HPVmHNSCCs occur in a subset of HPVmHNSCC cases with distinct characteristics. Thorough interrogation of all oropharyngeal subsites should be performed as part of the initial workup for HPVmHNSCC, with consideration given to contralateral tonsillectomy at the time of surgical resection for HPV mediated tonsil cancers due to the prevalence of contralateral tonsil primaries.

Identifiants

pubmed: 31765835
pii: S1368-8375(19)30386-0
doi: 10.1016/j.oraloncology.2019.104475
pmc: PMC7017724
mid: NIHMS1551420
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104475

Subventions

Organisme : NCI NIH HHS
ID : K07 CA218247
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA060397
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Cancer. 2013 May 15;119(10):1832-7
pubmed: 23423883
Head Neck. 2016 Apr;38 Suppl 1:E873-83
pubmed: 25966421
Laryngoscope. 2019 May;129(5):1141-1149
pubmed: 30152175
Clin Cancer Res. 2010 Feb 15;16(4):1226-35
pubmed: 20145161
J Otolaryngol Head Neck Surg. 2013 May 29;42:36
pubmed: 23718873
Head Neck. 2015 Feb;37(2):202-8
pubmed: 24375667
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Genome Res. 2019 Jan;29(1):1-17
pubmed: 30563911
J Oral Maxillofac Surg. 2017 Dec;75(12):2562-2572
pubmed: 28618252
Ann Otol Rhinol Laryngol. 1992 Feb;101(2 Pt 1):105-12
pubmed: 1531402
Int J Cancer. 2008 Nov 15;123(10):2390-6
pubmed: 18729183
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
J Clin Oncol. 2011 Feb 20;29(6):739-46
pubmed: 21189382
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Oral Oncol. 2017 Nov;74:8-14
pubmed: 29103756
Ear Nose Throat J. 2016 Apr-May;95(4-5):E30-4
pubmed: 27140027
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):276-83
pubmed: 20950953
BMC Cancer. 2013 May 01;13:220
pubmed: 23634887
J Cancer Res Clin Oncol. 2014 Jun;140(6):1011-9
pubmed: 24615330
Laryngoscope. 2010;120 Suppl 4:S181
pubmed: 21225779
Auris Nasus Larynx. 2014 Feb;41(1):109-12
pubmed: 23871190
Head Neck. 2017 Nov;39(11):2224-2231
pubmed: 28782298
Oral Oncol. 2013 Mar;49(3):244-8
pubmed: 23062994

Auteurs

William Strober (W)

University of Pittsburgh, School of Medicine, Pittsburgh, PA, United States.

Sachie Shishido (S)

Massachusetts Eye and Ear, Boston, MA, United States.

Burton Wood (B)

Vanderbilt University Medical Center, Nashville, TN, United States.

James S Lewis (JS)

Vanderbilt University Medical Center, Nashville, TN, United States.

Krystle Kuhs (K)

Vanderbilt University Medical Center, Nashville, TN, United States.

Robert L Ferris (RL)

University of Pittsburgh, School of Medicine, Pittsburgh, PA, United States.

Daniel L Faden (DL)

Massachusetts Eye and Ear, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address: Daniel_Faden@meei.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH